A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Incyte Corporation
Incyte Corporation
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Istituto Oncologico Veneto IRCCS
AstraZeneca
Bayer
BeOne Medicines
AbbVie
Incyte Corporation
Bristol-Myers Squibb
Pfizer
Gilead Sciences
National Cancer Institute (NCI)
Takeda
National Cancer Institute (NCI)
AbbVie
National Cancer Institute (NCI)
University Medical Center Groningen
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Janssen Research & Development, LLC
Coherus Oncology, Inc.
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Merck Sharp & Dohme LLC
Tongji Hospital
AbbVie
National Health Research Institutes, Taiwan
Parabilis Medicines, Inc.
Tuen Mun Hospital
NRG Oncology
Pfizer
Peking University
Seagen Inc.
Vividion Therapeutics, Inc.
Seagen Inc.
Fudan University
Tvardi Therapeutics, Incorporated
Summit Therapeutics
Vejle Hospital
Genentech, Inc.
Replimune Inc.
University of Wisconsin, Madison
Amgen
Novartis
Revolution Medicines, Inc.
Hoffmann-La Roche
Bristol-Myers Squibb
M.D. Anderson Cancer Center
Ono Pharmaceutical Co. Ltd
National Institutes of Health Clinical Center (CC)
Tianjin Medical University Cancer Institute and Hospital